BEAT

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management attributes the company's competitive advantage to its proprietary TriCor 3D signal reconstruction technology, which enables medical-grade 12-lead ECG capture across three distinct form factors: a card, a patch, and a remote unit. The strategic pivot toward heart attack detection is driven by the technology's ability to provide actionable, near real-time data that can differentiate between cardiac events and non-critical symptoms. Operational focus has shifted toward integrating the HeartBeam system into the 'intake workflow' of concierge practices, ensuring every new patient receives a baseline reading to facilitate faster clinical adoption. The company is leveraging its ALIGN-ACS and HEADSTART-ACS clinical data to build a regulatory moat, emphasizing that their signal quality is 'truly amazing' to physicians accustomed to traditional, cumbersome 12-lead setups. Management highlighted a significant organizational shift toward capital efficiency, reducing operating cash outflows by curtailing non-essential projects and utilizing AI tools to maintain R&D momentum with fewer resources. Strategic positioning now includes targeting large integrated health networks to disrupt emergency room and post-procedure workflows, aiming to replace traditional ECG technicians with on-demand patient-activated monitoring. The company submitted a 510(k) pre-submission to the FDA for heart attack detection on the day of the call, initiating a 75-day review window that will define the parameters of a pivotal trial. Management anticipates commencing a pivotal study for myocardial infarction (MI) detection by year-end 2026, assuming favorable feedback from the FDA regarding identified predicates. Financial guidance assumes a step-down in baseline operating cash flow to below $2.5 million per quarter by Q4 2026, though this may increase depending on the speed of pivotal trial enrollment. Commercial momentum is expected to accelerate in the second half of 2026, with management projecting 'increasing magnitude' in order flow by the end of Q3 as initial concierge pilots transition to full patient-pool deployment. The cash runway has been extended into 2027, supported by a $11.5 million financing in April and a projected full-year 2026 operating cash outflow of less than $14 million. Q2 net loss included $0.9 million in one-time items related to a leadership transition, specifically $0.6 million in non-cash stock-based compensation and $0.3 million in severance for the former CEO. The company successfully completed the working prototype for the 12-lead ambulatory patch, targeting a $2 billion market for ischemia and complex arrhythmia detection. HeartBeam expanded its IP portfolio with two new patents for acoustic sensing (valve performance) and fluid monitoring (congestive heart failure), signaling future expansion beyond ECG signals. Management noted that while they are pursuing a global strategy, current international efforts are strictly prioritized on the Indonesian Ministry of Health partnership to establish a blueprint for remote-market adoption. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management clarified that 'licensing' currently refers to partnerships with integrated networks to embed technology into workflows rather than pure IP licensing. International focus is exclusively on Indonesia for now, using it as a test case for how the technology fits into large-scale, remote healthcare settings before expanding elsewhere. The concierge vertical represents approximately 1.9 million patients, with management estimating that 20% or more are at-risk cardiac patients. Management reiterated that approximately 30,000 patients are needed to reach cash flow positivity, a target that may be lower now due to recent cost-reduction efforts. The company is pursuing the 510(k) pathway for heart attack assessment and has already identified predicates to justify this strategy to the FDA. While trial size is not yet determined, management is 'cautiously optimistic' about starting the pivotal study before year-end based on rapid enrollment in previous pilot studies. The primary learning has been the necessity of 'streamlining the workflow' by making HeartBeam part of the standard new patient intake process to reduce physician hesitancy. Early feedback confirms that both physicians and patients are 'amazed' by the 12-lead signal quality from a pocket-sized device, which has validated the 24/7 reader service model.

This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. HeartBeam Inc (NASDAQ:BEAT) submitted its pre-submission to the FDA for heart attack detection, advancing its regulatory pathway. The ALIGN ACS pilot study completed enrollment in under four months, with results accepted for presentation at TCT. The Head Start ACS pilot study in Indonesia has surpassed 50% enrollment in less than three months, supported by the Indonesian government. Initial commercial launch is underway with agreements in four key U.S. markets, and first orders have shipped with positive physician and patient feedback. The company reduced operating cash outflow by 7% quarter-over-quarter and expects Q4 2026 baseline to drop below $2.5 million per quarter. Cash runway extended into 2027 due to a reduced cost profile and an $11.5 million capital raise in April 2026. The company completed a working prototype for its 12-lead ECG patch, targeting a $2 billion market. Two new patents were issued for acoustic sensing and fluid monitoring, expanding future capabilities. Physician and patient testimonials highlight high satisfaction with the device's ease of use and ECG quality. The company is exploring integrated network partnerships, with one potential partner having 50 million visits annually. HeartBeam Inc (NASDAQ:BEAT) reported a net loss of $5 million for Q2 2026, including $0.9 million in one-time items related to leadership transition. The company's cash position is $8.8 million as of June 30, 2026, which may be insufficient for long-term operations without additional funding. The pivotal study for heart attack detection has not yet begun, and the timeline for FDA approval remains uncertain. Commercial revenue generation is still in early stages, with only 'green shoots' and no significant revenue reported yet. The company faces competition from established players in the ECG monitoring market, and its technology is unproven at scale. The leadership transition resulted in additional costs and potential disruption to operations. The company's focus on concierge practices limits its initial market reach, and the number of covered lives is still in the thousands. The company's cash runway extension is partly due to employees taking shares instead of cash bonuses, which may not be sustainable. The company's international expansion is limited to Indonesia, with no clear plans for other markets. The company's reliance on a single technology platform for multiple form factors may pose risks if the technology fails to gain regulatory approval. Warning! GuruFocus has detected 2 Warning Signs with BEAT. Is BEAT fairly valued? Test your thesis with our free DCF calculator. Q: What regulatory pathway did HeartBeam propose in its FDA pre-submission for heart attack detection, and when could the pivotal trial begin?A: Executive Chairman Richard Ferrari confirmed the company submitted its pre-sub to the FDA on the day of the call, proposing a 510(k) pathway. The FDA has 75 days to respond. While the exact size of the required pivotal trial is not yet determined, Ferrari noted that given the identified predicates and the rapid enrollment seen in prior studies, the company is cautiously optimistic it could commence the pivotal trial before the end of 2026. Q: Can you provide more specifics on the strategic shift toward licensing data from the synthesized 12-lead ECG, including target partners and commercial applications?A: Ferrari clarified that "licensing" was an overstatement. The initiative refers to partnering with large integrated networks to incorporate HeartBeam's technology into their workflows, particularly in emergency rooms and post-procedure in-hospital monitoring. He highlighted one network under discussion with 50 million visits annually and over 100,000 interventional procedures, illustrating the potential scale. A pure licensing strategy remains undetermined, though the Indonesian Ministry of Health partnership could evolve into one. Q: What is the size of the initial commercial opportunity in concierge practices, and what is the runway for patient onboarding over the next 12 months?A: Ferrari stated that the concierge market encompasses approximately 1.9 million patients, with an estimated 20% or more being cardiac-oriented. CFO Tim Cruikshank added that the company's goal is to reach roughly 30,000 patients to achieve cash flow positivity, a number that may now be lower given the reduced cost profile. He emphasized that the current focus is on perfecting workflows, with thousands of patients already covered under signed agreements across the four target geographies. Q: What were the key learnings from the pilot studies, and how have they influenced the FDA submission and commercial onboarding strategy?A: Founder and President Breneslaw Vadish highlighted that the ALIGN ACS pilot study, completed in under four months with 134 patients, validated both the technology's performanceaccepted for a full presentation at TCTand the execution process. These learnings will inform the pivotal trial. Ferrari added that the biggest commercial learning is streamlining workflow by integrating HeartBeam into new patient intake processes at concierge practices, establishing a baseline 12-lead EKG for all incoming patients to accelerate adoption. Q: How is the company managing its cash burn, and what is the updated financial outlook?A: CFO Tim Cruikshank reported net cash used in operating activities of $3.3 million in Q2 2026, a 7% decrease from Q1. The company achieved efficiencies by pausing tangential projects, leveraging AI tools, and having executives take shares in lieu of cash bonuses, reducing outflow by over $1 million. The company expects baseline Q4 2026 operating cash flow to step down to below $2.5 million per quarter, with full-year 2026 operating cash outflows trending below $14 million. Cash and restricted cash stood at $8.8 million as of June 30, extending the runway into 2027. Q: What is the status of the international expansion, and which markets are being prioritized?A: Ferrari stated that the company is solely prioritizing the Indonesian Ministry of Health partnership, where the HEAD START ACS pilot study has surpassed 50% enrollment in under three months. This 500-patient study will evaluate the technology's accuracy in a real-world setting and could lead to integration into large hospitals and remote settings, addressing a market of 280 million people. All other international efforts are paused, with the remaining focus directed at the U.S. market. Q: Can you elaborate on the new patents for acoustic sensing and fluid monitoring, and their potential applications?A: Ferrari explained that two new patents were issued for future technology extensions. Acoustic sensing will interrogate information about heart valve performance, while fluid monitoring uses impedance to detect fluid increases in patients, particularly those with congestive heart failure. This could enable at-home monitoring and drug titration, potentially preventing emergency room visits. Q: What is the manufacturing capability to support a potential ramp-up in 2027?A: When asked if the company could easily handle a manufacturing ramp in 2027, Ferrari responded affirmatively with a simple "Yes," indicating that the company has the necessary capabilities in place to scale production as commercial adoption accelerates. Q: What were the one-time items impacting the Q2 2026 net loss, and what is the underlying performance?A: CFO Tim Cruikshank noted that the reported net loss of $5.0 million included approximately $0.9 million in one-time items related to the leadership transition: $600,000 in non-cash stock-based compensation and $300,000 in severance accrual for the former CEO. Excluding these items, the underlying net loss was approximately $4.1 million, representing a 12% decrease quarter-over-quarter and a 17% decrease year-over-year. Q: How many covered lives do the current commercial agreements capture, and what is the strategy for growth?A: Tim Cruikshank explained that the four primary geographies (New York, Dallas, South Florida, Southern California) cover the majority of the target patient pool. While the company is not yet providing detailed metrics, agreements currently cover thousands of patients. The strategy is to perfect workflows first, with the goal of reaching 30,000 patients to achieve break-even, a target that may be lower given the current cost structure. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Completed Enrollment in ALIGN-ACS Heart Attack Detection Pilot Study Ahead of Schedule; Full Results to be Presented at TCT 2026 Surpassed 50% Enrollment Ahead of Schedule in Indonesian Government-Supported HEADSTART-ACS Pilot Study for Heart Attack Detection Initial Commercial Launch of the HeartBeam System Underway with Multiple Signed Agreements Across Four Targeted U.S. Geographies Completed Working Prototype of 12-Lead ECG Extended Wear Patch Targeting the $2 Billion Ambulatory Cardiac Monitoring Market Lowered Expected Full Year 2026 Net Operating Cash Outflow to Below $14.0 Million Management to Host Webcast and Conference Call Today at 4:30 p.m. ET SANTA CLARA, Calif., August 13, 2026--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the second quarter ended June 30, 2026. Second Quarter & Subsequent 2026 Operational Highlights In June 2026, the Company announced a strategic shift to accelerate the global adoption of its ambulatory ECG signal platform. During the quarter, HeartBeam delivered ahead of schedule on its heart attack detection clinical program, completed the working prototype of its 12-lead ECG patch, advanced its initial commercial launch in the arrhythmia market, expanded its robust patent portfolio, and further reduced its cost profile. Heart Attack Detection: Completed enrollment in the ALIGN-ACS pilot study in less than four months, ahead of the previously communicated third quarter 2026 timeline. Surpassed 50% enrollment in less than three months, well ahead of schedule, in the HEADSTART-ACS pilot study, a 500-patient study supported by the Indonesian government evaluating the accuracy of HeartBeam’s ECG technology in detecting heart attacks in a real-world setting. Indonesia represents a strategically significant international market of 280 million people. Publication in JACC: Advances demonstrated that an algorithm combining the HeartBeam ECG device with patient risk factors and symptoms can accurately identify heart attack risk in patients presenting with chest pain. Results from these studies will inform the design of a pivotal study in the U.S. and support a future FDA submission to expand the HeartBeam System’s indication beyond arrhythmia assessment to include heart attack assessment. The Company is actively engaged with FDA on study design and indication expansion pathways and expects to provide additional detail on timelines by year-end. 12-lead ECG Extended Wear Patch: Completed the working prototype of the Company’s novel 12-lead ECG extended wear patch, the first ambulatory patch device designed to aid in detecting ischemia and complex arrhythmias. The patch provides continuous single-lead monitoring that matches the performance of existing systems, together with an on-demand 12-lead ECG mode that expands the segment into ischemia detection. In May 2026, initiated a pilot study evaluating the patch in approximately 50 patients with a high risk of coronary artery disease at two leading hospitals in Belgrade, Serbia. The Company believes the patch can disrupt the ambulatory cardiac monitoring market, a $2 billion revenue market with established reimbursement that consists of the long-term continuous monitor and mobile cardiac telemetry segments. The Company is in discussions with potential strategic partners and continues to explore opportunities for partnerships. Initial Commercial Launch: Advanced the initial commercial launch of the HeartBeam System for arrhythmia assessment, with an end-to-end reader service, onboarding workflow, and customer-success function all live. The Company’s 24/7 reader service remains a key differentiator of its product offering. Signed multiple commercial agreements across the Company’s four targeted U.S. geographies: New York metro, Dallas, South Florida, and Southern California. Shipped first orders and onboarded initial patients during the second quarter of 2026, and is seeing orders of increasing magnitude in the third quarter of 2026. Contracting with practices that see the clinical value of a personal 12-lead ECG – proven early adopters with a high willingness to pay – and working directly with those practices on rollout planning, workflow integration, and implementation. Created a program incorporating HeartBeam directly into new patient intake at concierge practices, embedding HeartBeam into practice workflows, and expected to lead to faster adoption. Exhibited at ACC, HRS, and ASPC, driving opportunity and partnership qualification. Other Commercialization and Operational Highlights: In June 2026, the Company strategically aligned its operations around focused implementation teams led by Branislav Vajdic, Ph.D., Founder and President, who also serves as the Company’s principal executive officer effective July 1, 2026, and Rich Ferrari, Executive Chairman of the Board. In July 2026, HeartBeam was awarded a new U.S. patent expanding the acoustic sensing and fluid monitoring capabilities of its cable-free ECG device. The patent covers the integration of acoustic sensing and thoracic impedance measurement into the existing ECG hardware platform, supporting future applications in structural heart disease and heart failure monitoring. The Company’s patent portfolio now includes 26 issued patents worldwide, strengthening the moat around its core technology. Cash and cash equivalents totaled $8.7 million as of June 30, 2026, compared to $4.4 million as of December 31, 2025. Net cash used in operating activities was $3.3 million for the second quarter of 2026, a 7% decrease compared to the first quarter of 2026 and a 3% decrease compared to the second quarter of 2025. In April 2026, the Company closed an underwritten public offering of common stock for total gross proceeds of $11.5 million including full exercise of the over-allotment option, before deducting underwriting discounts, commissions, and offering expenses. Management Commentary "Every 40 seconds, someone suffers from a heart attack, and we believe HeartBeam’s technology, incorporating our signal capture technology TriCor, is the best way to evaluate the real extent of that trauma in a wireless format," said Rich Ferrari, Executive Chairman of HeartBeam. "Our heart attack detection program is where we are accelerating the fastest. We completed ALIGN-ACS enrollment ahead of schedule, with data analysis underway, and will be presenting full results of the pilot study at TCT 2026 this fall. These results are intended to inform the design of our U.S. pivotal study as we continue to work collaboratively with the FDA on a submission to expand our indication for heart attack assessment. "We continue to sharpen our focus as we execute on our key priorities. In addition to our advancements with heart attack detection, in the second quarter we continued to advance our initial commercial launch, completed development of our 12-lead ECG patch prototype, and drove a lower cost profile that extends our cash runway further into 2027. The real-world validation is showing up: our 24/7 reader service is live, we have signed agreements across our four targeted geographies, first orders have shipped with initial patients onboarded, and we are seeing orders of increasing magnitude in the third quarter. Clinical, commercial, and financial proof points are exactly what a potential partner needs to see before committing to a platform, and together they define the opportunity in front of us – one platform, adaptable to every market," Ferrari concluded. Second Quarter 2026 Financial Results Selling, general and administrative expenses for the second quarter of 2026 were $2.8 million, compared to $1.7 million for the second quarter of 2025. The increase in SG&A primarily related to non-cash stock-based compensation expense of $0.6 million driven by equity award acceleration for the former CEO and the severance accrual payable to the former CEO of $0.3 million during the three and six months ended June 30, 2026. These costs are one-time in nature and therefore not expected to continue beyond June 30, 2026. Research and development expenses for the second quarter of 2026 were $2.3 million, compared to $3.3 million for the second quarter of 2025. The decrease was primarily related to a $0.7 million decrease in product development and consulting expenses related to the development of the HeartBeam System, a $0.1 million decrease in headcount-related costs, and a $0.1 million decrease in non-cash stock-based compensation expense. Total operating expenses for the second quarter of 2026 were $5.1 million, compared to $5.0 million for the second quarter of 2025. Net loss for the second quarter of 2026 was $5.0 million, or $(0.10) per basic and diluted share, compared to a net loss of $5.0 million, or $(0.15) per basic and diluted share, for the second quarter of 2025. Net cash used in operating activities was $3.3 million for the second quarter of 2026, a 7% decrease compared to the first quarter of 2026 and a 3% decrease compared to the second quarter of 2025. Net cash used in operating activities was $7.0 million for the six months ended June 30, 2026, compared to $7.9 million for the six months ended June 30, 2025. Cash, cash equivalents and restricted cash totaled $8.8 million as of June 30, 2026, compared to $4.4 million as of December 31, 2025. In April 2026, the Company closed an underwritten public offering of common stock for total gross proceeds of $11.5 million including full exercise of the over-allotment option, before deducting underwriting discounts, commissions, and offering expenses. Financial Outlook Third quarter 2026 cash outflow is expected to be in line with the second quarter of 2026, due to the short-term impact of updating the Company’s cost structure. Baseline fourth quarter 2026 operating cash outflow is expected to step down to below $2.5 million, with cash receipts from customer contracts expected to reduce this further. Full year 2026 net operating cash outflow is now expected to be below $14.0 million, a further reduction from the Company’s previous guidance. Cash runway is extended further into 2027 and aligned with the achievement of key milestones. Second Quarter 2026 Results Conference Call HeartBeam Executive Chairman Rich Ferrari, Founder and President Branislav Vajdic, Ph.D., and Chief Financial Officer Tim Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company’s website here. To access the call, please use the following information: A telephone replay will be available approximately three hours after the call and will run through November 13, 2026, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 13761826. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the Company’s investor relations section here. About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2025. The Company holds 26 issued patents worldwide related to technology enablement. For additional information, visit HeartBeam.com. Forward-Looking Statements All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Cleared Indications for Use The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology. MKT-158 v0 View source version on businesswire.com: https://www.businesswire.com/news/home/20260813456155/en/ Contacts Investor Relations Contact:Chris TysonExecutive Vice PresidentMZ North AmericaDirect: [email protected] www.mzgroup.us Media Contact: [email protected]

SANTA CLARA, Calif., July 30, 2026--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, August 13, 2026 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2026, and will be providing updates on its strategy to accelerate global adoption of its ambulatory ECG signal platform. A press release detailing these results will be issued prior to the call. HeartBeam Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, Ph.D., and Chief Financial Officer Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed following the call via the investor relations section of the Company’s website here. To access the call, please use the following information: A telephone replay will be available approximately three hours after the call and will run through August 27, 2026, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 13761826. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the Company’s investor relations section here. About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 20251. The Company holds over 25 issued patents related to technology enablement. For additional information, visit HeartBeam.com. 1Cleared Indications for Use The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment. Refer to the Company’s Cleared Indications for Use and full instructions at https://www.heartbeam.com/indications for details on the intended use of its technology. MKT-155 v0 View source version on businesswire.com: https://www.businesswire.com/news/home/20260730456806/en/ Contacts Investor Relations Contact: Chris TysonExecutive Vice PresidentMZ North AmericaDirect: [email protected] www.mzgroup.us Media Contact: [email protected]

LOS ANGELES, CA - May 14, 2026 (NEWMEDIAWIRE) - HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results highlighted by the launch of its initial commercial partnerships in key U.S. markets, progress in its heart attack detection and ambulatory ECG patch initiatives, and an April public offering that raised $11.5 million in gross proceeds. The company reported a first-quarter net loss of $4.7 million, improved from $5.5 million in the prior-year period, with research and development expenses declining year over year as HeartBeam continued advancing commercialization of its FDA-cleared cardiac monitoring platform and related growth initiatives. To view the full press release, visit https://ibn.fm/guMCF About HeartBeam, Inc. HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1). The Company holds over 20 issued patents related to technology enablement. (1)Cleared Indications for Use The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company's Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law

This article first appeared on GuruFocus. Cash Balance: Ended March 31, 2026, with a cash balance of just over $2 million. Pro Forma Cash Balance: Approximately $12.4 million after recent financing and over-allotment. Net Loss: $4.7 million for Q1 2026. Net Cash Used in Operating Activities: $3.6 million, a 19% decrease compared to the same quarter in the prior year. Financing: $11.5 million raised through an underwritten public offering of common stock. Cash Outflow Expectation for 2026: Estimated to be below $16 million. Cash Runway: Funding into 2027, with a focus on commercialization and development initiatives. Warning! GuruFocus has detected 2 Warning Signs with BEAT. Is BEAT fairly valued? Test your thesis with our free DCF calculator. Release Date: May 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. HeartBeam Inc (NASDAQ:BEAT) signed its first commercial partnership in Q1 with ClearCardio, establishing a presence in key markets like New York City, Dallas, and South Florida. The company has developed a portable, cable-free ECG system that synthesizes a 12-lead ECG, receiving two FDA clearances for arrhythmia assessment. HeartBeam Inc (NASDAQ:BEAT) initiated a strategic collaboration with Mount Sinai to develop next-generation AI algorithms for heart attack detection and personalized cardiac assessment. The company completed a working prototype of its 12-lead patch and initiated a pilot study focused on ischemia detection, targeting a $2 billion market. HeartBeam Inc (NASDAQ:BEAT) strengthened its financial position with an $11.5 million financing, providing a cash runway to advance into the next phase of growth. HeartBeam Inc (NASDAQ:BEAT) reported a net loss of $4.7 million for Q1 2026, with net cash used in operating activities amounting to $3.6 million. The company is still in the early stages of commercialization, with revenue generation not being the primary focus for the first half of 2026. HeartBeam Inc (NASDAQ:BEAT) faces challenges in scaling its operations, requiring careful management of cash and dilution to maintain a low-cost profile. The company is dependent on successful partnerships and adoption within anchor accounts to achieve its revenue and growth targets. HeartBeam Inc (NASDAQ:BEAT) is still in the process of validating its premium value proposition and refining its systems and processes for broader adoption. Q: Can you talk about how many patients are collectively managed by your anchor partners and any updates on pricing? A: Bryan Humbarger, Chief Commercial Officer, explained that while specific patient numbers aren't publicly shared, the focus is on targeting 150,000 patients in the preventative concierge market, aiming for 30,000 patients to reach breakeven. The pricing remains in the $750 to $1,000 range annually, with no pushback received on this pricing. Q: Regarding the ALIGN-ACS pilot study, can you provide details on the study size and timeline for the pivotal study? A: Robert Eno, CEO, stated that the ALIGN-ACS study involves 100 to 120 patients and is ahead of schedule, expected to complete by the end of Q3. The study design will inform discussions with the FDA for the pivotal study, with ongoing communication about regulatory pathways and clinical study design. Q: How should revenue from subscription billing be modeled, and what is the revenue expectation for 2026? A: Timothy Cruickshank, CFO, explained that revenue will be largely straight-lined over the year, with some revenue recognized earlier due to onboarding costs. Most customers are expected to pay upfront, aiding cash flow. The focus is on proving deep adoption rather than immediate revenue generation. Q: Can you elaborate on the feedback from medical professionals regarding the HeartBeam product? A: Bryan Humbarger noted that feedback has exceeded expectations, with clinicians appreciating the ability to arm patients with medical-grade technology for use outside of clinical settings. There is interest in using the device for regular monitoring to gain longitudinal data insights. Q: Why did the company wait to raise funds until the stock price was lower? A: Timothy Cruickshank explained that financing decisions consider shareholder input, existing covenants, and bringing on supportive long-term investors. The recent financing was a clean deal with common stock only, aiming to support the company's growth and valuation goals. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Signed First Commercial Partners in Leading Concierge Practices ClearCardio™ and Atelier Health Established Flagship Commercial Sites Across New York, Dallas, South Florida and Southern California Strategic Collaboration with Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms, Starting with Heart Attack Detection Strengthened Balance Sheet with $11.5 Million Public Offering Including Full Exercise of Over-Allotment Option Initiated Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Initiated Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic Management to Host Webcast and Conference Call Today at 4:30 p.m. ET SANTA CLARA, Calif., May 13, 2026--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, has reported its financial and operational results for the first quarter ended March 31, 2026. First Quarter & Subsequent 2026 Operational Highlights The Company continues to make significant progress entering commercialization while advancing several key initiatives as part of its growth strategy: Initial Commercial Launch: Signed first commercial partnership with ClearCardio™, a rapidly growing preventive cardiology practice with thousands of highly engaged members. The partnership includes an initial staged rollout in New York metro, Dallas and South Florida to ensure a seamless patient and physician experience. Signed commercial partnership with Atelier Health, a Beverly Hills-based premier concierge medical practice led by physicians affiliated with Cedars-Sinai, in the Company’s expansion to the West Coast. These commercial partnerships establish flagship sites across the Company’s targeted geographies of New York, Dallas, South Florida and Southern California, supporting scalable expansion of HeartBeam’s technology in preventive cardiology. The partnerships support HeartBeam's commercialization strategy within preventive cardiology and concierge medicine while helping refine onboarding and physician workflow integration. Establishes an initial foothold in structured direct pay healthcare segment, representing approximately 5 million patients in the U.S. Heart Attack Detection: Enrolled first patients in the ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. ALIGN-ACS pilot study expected to complete patient enrollment quickly as study is designed to enroll chest pain patients in the emergency department. Milestone signifies key step toward future FDA indication expansion for heart attack assessment. Future indication expansion would address a large market with over 20 million patients at risk of a heart attack. 12-lead ECG Extended Wear Patch: Completed the first working prototype of an extended-wear 12-lead ECG ambulatory patch, designed to aid in detecting ischemia and complex arrythmias. Initiated pilot study of first on-demand 12-Lead ECG Patch to detect ischemia outside the clinic and traditional medical facilities. Targets a $2 billion market with established reimbursement; ischemia detection has potential to disrupt the patch market which is currently limited to atrial fibrillation detection. AI Program: Announced strategic collaboration with the Icahn School of Medicine at Mount Sinai to support development and validation of next-generation AI-ECG algorithms. Collaboration combines Mount Sinai’s AI and clinical expertise with HeartBeam’s 3D ECG signal collection technology. AI efforts are focused on future applications including heart attack detection and personalized cardiac assessment. Other Commercialization and Operational Highlights: Appointed Bryan Humbarger as Chief Commercial Officer to lead commercial strategy and execution across the Company’s key growth initiatives. Cash and cash equivalents totaled $2.0 million as of March 31, 2026, with net cash used in operating activities of $3.6 million for the three-month period ended March 31, 2026, resulting in a 19% decrease compared to same quarter in the prior year. In April 2026, the Company closed an underwritten public offering of common stock for total gross proceeds of $11.5 million including full exercise of the over-allotment option, before deducting underwriting discounts, commissions, and offering expenses. Management Commentary "In just two months since our last earnings call, we made significant progress executing against the commercialization and growth strategy we’ve consistently discussed over the last several quarters. We established flagship commercial accounts across New York, Dallas, South Florida and Southern California, advanced our heart attack detection and on-demand 12-lead patch initiatives, and strengthened our balance sheet. HeartBeam’s differentiated FDA-cleared synthesized 12-lead ECG platform remains the foundation of our growth, backed by strong IP and clinical evidence," said Robert Eno, Chief Executive Officer, HeartBeam. "Looking ahead, we remain focused on expanding our commercial footprint by driving deep adoption within our flagship accounts and continuing to build out workflow integration and patient onboarding within those practices while continuing to make significant advancements with our patch, heart attack detection and AI initiatives throughout 2026," concluded Eno. First Quarter 2026 Financial Results Research & development expenses for the first quarter of 2026 were $2.4 million, compared to $3.5 million for the first quarter of 2025. Selling, general & administrative expenses for the first quarter of 2026 were $2.3 million compared to $2.0 million for the first quarter of 2025. Net loss for the first quarter of 2026 was $4.7 million, compared to a net loss of $5.5 million for the first quarter of 2025. Net cash used in operating activities was $3.6 million for the three-month period ended March 31, 2026, a 19% decrease compared to the same quarter in the prior year. Cash and cash equivalents totaled $2.0 million as of March 31, 2026, as compared to $4.4 million at December 31, 2025. On April 16, 2026, the Company closed an underwritten public offering of common stock for total gross proceeds of $11.5 million including full exercise of the over-allotment option, before deducting underwriting discounts, commissions, and offering expenses. First Quarter 2026 Results Conference Call HeartBeam CEO Robert Eno, CFO Timothy Cruickshank, and CCO Bryan Humbarger will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed following the call via the investor relations section of the Company’s website here. To access the call, please use the following information: A telephone replay will be available approximately three hours after the call and will run through May 27, 2026, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 13760379. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the Company’s investor relations section here. About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com. Forward-Looking Statements All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. 1Cleared Indications for Use The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology. MKT-148 v1 View source version on businesswire.com: https://www.businesswire.com/news/home/20260513180482/en/ Contacts Media Contact: [email protected] Investor Relations Contact: Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 [email protected] www.mzgroup.us

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Secured flagship accounts in all four target geographies (NYC, Dallas, South Florida, Southern California) to validate the premium value proposition for the HeartBeam system. Transitioned to a limited commercial launch focused on the Direct Pay segment, targeting approximately 5 million U.S. patients through technology-forward concierge and preventive cardiology practices. Leveraged the core 3D signal collection technology to develop a second form factor, an on-demand 12-lead extended wear patch, aimed at the $2 billion ambulatory cardiac monitoring market. Initiated the ALIGN-ACS pilot study in Europe to compare HeartBeam to standard 12-lead ECGs in emergency departments, a critical step toward expanding indications for heart attack detection. Finalized a strategic collaboration with Mount Sinai to pair clinical expertise with 3D ECG data for the development of next-generation AI algorithms for MI detection and wellness. Adopted a capital-efficient commercial model using a lean sales team to prove scale and efficiency before broader expansion in 2027. Management lowered the 2026 cash outflow estimate to below $16 million, down from the previous $17 million to $19 million range, by utilizing a leaner initial sales structure. The second half of 2026 will focus on proving deep adoption within anchor accounts and establishing a sales funnel to support 2027 revenue goals. Expect to complete enrollment for the ALIGN-ACS pilot study by the end of Q3 2026, which will inform the design of a subsequent FDA pivotal study. Strategic partnership discussions for the 12-lead patch are ongoing, with the goal of leveraging industry players to accelerate market entry and adoption. Revenue recognition for the subscription model is expected to be largely straight-lined over contract terms, though cash flow will benefit from upfront annual payments. Strengthened the balance sheet with an $11.5 million financing in April 2026, providing a pro forma cash balance of approximately $12.4 million and runway into 2027. Achieved a 19% year-over-year reduction in operating cash burn in Q1 2026 despite making timely investments in commercial launch and patch development. The financing was led by HeartBeam's first commercial customer, ClearCardio, signaling strong partner conviction in the business model. Management emphasized a 'clean cap table' strategy by utilizing common stock only for the recent offering to maintain future optionality. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management confirmed subscription pricing remains in the $750 to $1,000 annual range with no initial pushback from physicians. While specific patient counts for private accounts were not disclosed, the target geographies represent tens of thousands of potential patients in the concierge segment. The company views 30,000 patients as the breakeven point, with a strategy to reach the first 10,000 through small accounts before scaling via larger medical chains. Revenue will show a slight front-loading due to onboarding obligations but will primarily be recognized straight-line over the subscription period. Existing 1-to-3 lead patches are limited to arrhythmia; HeartBeam's patch adds 12-lead on-demand capability for ischemia detection. Physicians expressed interest in longitudinal data from frequent 12-lead measurements, which was previously impossible outside of a clinical setting. Management defended the timing by emphasizing the importance of bringing in long-term institutional partners and maintaining a clean common-stock-only structure. The raise was intended to provide the necessary runway to reach upcoming clinical and commercial milestones regardless of short-term stock price fluctuations.

HeartBeam (NASDAQ:BEAT) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. The full earnings call is available at https://viavid.webcasts.com/starthere.jsp?ei=1761581&tp_key=a64f57a332 Heartbeam Inc reported a successful first quarter, with a focus on commercialization and growth initiatives. The company signed its first commercial partnership with ClearCardio and expanded its presence with Atelier Health, establishing flagship sites in key U.S. markets. Heartbeam Inc is advancing its 12-lead patch development and AI collaborations, with ongoing clinical studies for heart attack detection ahead of schedule. The company recently strengthened its financial position with an $11.5 million financing, providing a cash runway into 2027. Management emphasized a strategic, lean approach to commercialization, aiming for a break-even point with 30,000 patients and exploring potential partnerships for further expansion. OPERATOR Greetings and welcome to the Heartbeam First Quarter 2026 Financial Results Conference Call. At this time all participants are in listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference call is being recorded. Before we begin the formal presentation, I would like to remind everyone that the statements made on the call and webcast may include predictions, estimates or other information that might be considered forward looking. While these forward looking statements represent our current judgment on what the future holds, they are subject to risk and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward looking statements which reflects our opinions or only as of date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward looking statements in the light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our prediction. You should also review our Most recent Form 10K and Form 10Q for a more complete discussion of these factors and other risks, particularly under the heading Risk Factors. A press release detailing these results crossed the wire this afternoon and is available in the Invest Relations section of our company's website, heartbeam.com your hosts today, Rob Eno, Chief Executive Officer Tim Cruikshank, Chief Financial Officer, and Brian Humbagger, Chief Commercial Officer, will present results of operation for the first quarter ended March 31, 2026. At this time, I will turn the call over to Heartbeam Chief Executive Officer Mr. Rob Eno. Please go ahead. Rob Eno (Chief Executive Officer) Thank you, operator. The topics we'll cover on today's call are listed on the slide. We'll start with a brief summary of our recent progress, followed by a reminder of the Heartbeam system and our unique technology platform. Brian Humbarger, our Chief Commercial Officer, will provide an overview of our limited commercial launch. We'll then provide updates on our major growth initiatives, the On Demand 12 lead patch, and our heart attack detection and AI efforts, followed by the financial results. We'll end with Q and A. I'll briefly summarize our recent progress. We'll cover each of these in more detail throughout the presentation. We continue to execute well across both commercialization and our growth initiatives. On commercialization, we signed our first commercial partnership in Q1 with ClearCardio, anchoring us in New York City, Dallas and South Florida. We've since added Atelier Health, a Beverly Hills concierge practice led by physicians affiliated with Cedars Sinai, extending us to Southern California and giving us flagship sites in all four of our target geographies. Together, these partnerships establish our initial foothold in the direct pay segment, which represents roughly 5 million US patients on heart attack detection. We enrolled the first patient in our Align ACS pilot study, which compares Heartbeam to a standard 12 lead ECG and in chest pain patients in the emergency department, enrollment's ahead of schedule. The study is a key step toward FDA indication expansion into a market of 20 million at risk patients on the 12 lead patch. We completed our first working prototype in Q1 and we've now initiated a pilot study focused on ischemia detection. We believe this will be the best in class patch in a $2 billion market with established reimbursement partnership discussions continue to progress on AI we announced a strategic collaboration with Mount Sinai, pairing their AI and clinical expertise with our 3D ECG signal collection technology to develop next generation algorithms for heart attack detection, wellness and personalized cardiac assessment. Before we dive into detail updates, I want to remind everyone about our initial product, the Heartbeam system and our platform technology. Heartbeam is dedicated to developing groundbreaking ECG technology for patients to use at home. To empower them to feel confident about their heart health, Heartbeam has developed the first ever portable cable free ECG that can synthesize a 12 lead ECG. Our unique IP protected approach captures the heart's electrical signals in three dimensions or non coplanar directions and synthesizes the signals into a 12 lead ECG. The system is designed to be easy to carry and easy for patients to use at the time of symptom onset, anywhere, anytime. The technology is supported by a team of US based board certified cardiologists who are available 247 to interpret the clinical grade ECG and triage patients appropriately to ensure timely care. The system has received two FDA clearances for arrhythmia assessment. With these two clearances in place, we're embarking on our limited commercial launch. As you'll hear, we're extremely pleased with the reception of the system among leading concierge physicians and preventive cardiologists. Heartbeam is more than just the first cable free synthesized 12 lead ECG. It is true platform technology. The major advance that we pioneered and what our key IP is based around is our novel signal collection technology which captures the heart's electrical signals in three axes, left and right, up and down and into the body. These 3D signals can be converted into a familiar 12 lead waveform. This core technology can be applied to multiple form factors. We're embarking on the launch of the Heartbeam system, the credit card size form factor recently we announced the second form factor, an on demand 12 lead extended wear patch. We believe that this patch can disrupt the ambulatory cardiac monitoring market, a $2 billion revenue market. The technology in these two form factors has the potential to enable a full range of 12 lead ECG capabilities, including currently cleared arrhythmia assessment and future indications of heart attack detection and personalized AI algorithms. We'll discuss our progress toward heart attack detection and AI algorithms shortly, but now I want to turn it over to Brian Humbarger, Heartbeam's Chief Commercial Officer, to provide an update on our commercial efforts. Brian Humbarger (Chief Commercial Officer) Brian thank you Rob. Our commercial goals remain consistent and execution of the plan is well underway. As a review, we stated that in the first half of 2026, where we are today, that we are focused on validating our premium value proposition, refining the heartbeam systems and processes, signing and onboarding our anchor accounts, and proving the scaling efficiency of the model. In the second half of 2026, we will shift to proving deep adoption inside those anchor accounts and establishing the funnel that will support our 2027 revenue and adoption goals, developing white papers and clinical proof points to drive further adoption, and beginning to expand the sales team around our anchor geographies. And then in 2027 and beyond, we will scale revenue move to train the trainer model for implementation, expand our clinical research opportunities, and expand the sales, clinical and account management teams. These are the specific goals we set for in the first half of 2026 alongside our status against each one. Our first two goals are focused on signing and onboarding anchor accounts in key targeted markets and executing a concentrated rollout strategy in four key New York City, Dallas, South Florida and Southern California. We've now built flagship accounts in all four markets since our last call. We've added Atelier Health, located in Beverly Hills and led by physicians affiliated with Cedars Sinai. This establishes access of the heartbeam technology in Southern California. Additionally, our first customer, Clear Cardio, has recently expanded its footprint from Dallas to New York and South Florida, bringing along our technology as part of their offering in these markets. And these are technology forward customers that are rapidly growing in the preventative cardiology space. We also set out to validate our premium value proposition. Early Physician Engagement and flagship Account Traction have clearly reinforced demand for our personalized 12 lead ECG capability. Physicians who have spent time with the technology are confirming what we believe that this is a meaningfully differentiated tool. And finally, we prioritize the need to refine physician workflows. We've been working directly with clearcardio and Atelier on rollout planning, workflow integration, and the implementation processes and what we are learning is informing a cleaner, faster onboarding playbook. We will continue to prove our ability to scale efficiently. We are demonstrating this by accessing large patient populations through a focused set of strategically selected practices with a lean commercial team. Our focus will be on growth, which is the expansion of Heartbeam access in the target geography and adoption the penetration of patients in our contracted accounts for the limited commercial launch. We plan to execute this strategy with a sales director and one implementation specialist. After this phase, we plan to have a sales director and one to two implementation specialists per geography to support our growth and adoption efforts. Finally, we will begin measuring growth and adoption in addition to other key metrics as we move into this next phase of commercialization. Now I'll turn it back to Rob. Rob Eno (Chief Executive Officer) Thanks so much Brian. Next, I want to discuss our key growth initiatives, the 12 lead on demand Patch and our efforts on heart attack detection and AI. I'll start with the 12 lead patch. As I mentioned when we unveiled it last quarter, we believe that the Heartbeam 12 lead patch can disrupt the ambulatory cardiac monitoring market. This market consists of patches that are worn for up to 30 days and continually record the patient's heart rhythms. It's a rapidly growing $2 billion revenue market with existing reimbursement consisting of two segments, long term continuous monitors and mobile cardiac telemetry or mct. These existing devices are one to three leads and are limited to arrhythmia detection and monitoring. Heartbeam has developed an on Demand 12 lead patch and has produced a working prototype of the device. It functions just like existing patches, continually recording the patient's heart rhythms with a single lead. But using Heartbeam's patented technology, a patient simply places two fingers on the front of the device to record a clinical grade 12 lead ECG. This has the potential to bring better diagnostic capabilities, including ischemia detection, to the patch segment. The device integrates into existing workflows and leverages the existing reimbursement. We believe this will be the best in class patch. During the last call, we presented the results of market research surveys of cardiologists, electrophysiologists and emergency medicine physicians. The research indicated that a 12 lead patch could cause fully half of the market to shift and could grow the market as a whole by a third. We announced on Monday that we've initiated a pilot clinical study in Europe aimed at demonstrating the ability of the heart beam patch to detect ischemia. The pilot study will enroll approximately 50 patients with a high risk of coronary artery disease. Each patient undergoes exercise stress testing, a standard diagnostic procedure used to identify ischemic changes while wearing the Heartbeam patch. Immediately following exercise, patients will obtain a synthesized 12 lead ECG by placing two fingers on the front of the patch. This ECG will be compared directly with a standard 12 lead ECG recorded at the same time. The study will help inform the company's regulatory strategy for the heart beam patch. Also, as previously noted, we're in discussions with a number of industry players on a potential partnership to bring the patch to market. We've had several productive meetings since our last call, including at the American College of Cardiology and the Heart Rhythm Society meetings, and we'll keep you informed of the progress. At Heartbeam, we think about the card and the patch system not just as two products but as entry points into the patient's cardiac monitoring journey. First, as you see on the left, patients use the Heartbeam system, the card, as an episodic monitor for peace of mind and to get physician feedback as symptoms occur. They're able to use the device throughout their lives to provide the physician with information to identify and monitor heart abnormalities. Often a cardiologist will want more information, such as the arrhythmia burden, that will necessitate use of the patch so the card can directly lead to the patch. On the right hand side is the 12 lead patch, a continuous monitor that's worn for a period of weeks. It can create a 12 lead ECG on demand, and this could be prescribed when physicians want discontinuous information to assist in a new diagnosis or after an emergency department visit or a procedure such as revascularization or a cardiac ablation. A patient who finishes with the heartbeat patch could transition to the card for a number of reasons, for example to monitor intermittent episodes over their lifetime or if the patch is prescribed after a procedure. Once this acute phase is over, the the patient who's still high risk could transition to the card so the patch can directly lead to the card. This is a flywheel that can drive further usage and deeper engagement with the technology. As we've discussed previously, one of the major problems in cardiology is that there's no good way for patients who experience chest pain to know if they're having a heart attack. Patients wait an average of three to four hours before seeking care, and every 30 minutes of delay increases the risk of death by seven and a half percent. The 12 lead ECG is the standard for heart attack detection. But traditional 12 lead ECGs have 10 wired electrodes that need to be placed by a technician and they're not applicable for home use. This is a major problem with 20 million people in the US at risk of a heart attack, including 8 million who have had a previous heart attack. HeartBeam's technology has the potential to address this major need. We have multiple proof of concept studies showing that the heartbeam ECG is similar to a standard 12 lead ECG and in detecting heart attacks. One important point about this effort is it's the same Heartbeam system that we're launching with an expanded indication. The Align ACS pilot study is underway in Europe comparing the Heartbeam ECG to a standard 12 lead ECG and detecting heart attacks. The study is conducted in the emergency room, enrolling patients who arrive with chest pain. This will allow the study to enroll much more rapidly than a study that prescribed devices to pay patients and waited for them to have events. We expect the study to complete enrollment by the end of the third quarter of 2026 and the study will inform the design of our FDA pivotal study. The study is enrolling well and is currently ahead of schedule. Next I'd like to describe the vision of how our system will work with heart attack detection, but first here's the workflow. Today a patient with symptoms uses the Heartbeam system and the data is sent to a cardiologist who's available 24 7. The cardiologist reviews the ECG and the symptoms and responds to the patient in just a few minutes with an ECG interpretation of the patient's arrhythmic state. In our vision of heart attack detection, the workflow is very similar from a patient perspective but with the expanded indication. The on call cardiologist will review for the presence of heart attacks, reviewing the ECG in comparison with the baseline ECG symptoms and history. But the physician will also benefit from an AI algorithm specifically for MI detection. We plan to develop a deep learning model trained on ECGs taken when patients present with chest pain. The algorithm is trained on all of the data including which patients go on to be revascularized. In General, there are two types of heart attacks. ST elevation, myocardial infarctions or STEMI's are the classic heart attack which can be readily identified on an ECG, but non ST elevation myocardial infarctions or NSTEMI's are more subtle and sometimes are not picked up by a physician reviewing the ECG by training the algorithm on which patients actually need a revascularization we believe we'll be able to catch NSTEMIs as well as STEMI's back to the workflow. Our vision is that the patient's data will be sent to the physician, but in parallel we run through the AI algorithm which will provide insights on on the potential of both STEMI and NSTEMI heart attacks. So the physician's interpretation and recommendation will be informed by the AI algorithm. We'll have further updates on these efforts, including the clinical and regulatory timelines. Our robust clinical trial pipeline, which includes the Align ACS pilot study, the Indonesia Head Start ACS study and a US pivotal study, should provide on the order of 1,000 patients to further validate the AI algorithm we're developing. We showed this slide in the last call two months ago, laying out the key milestones for the year. We're making excellent progress achieving what we said we would. All of the milestones for Q1 are complete and we're well on the way to achieving the Q2 milestones on commercialization. As Brian walked through, we have signed and are onboarding our first two accounts, giving us flagship sites in all four of the key geographies that we laid out last quarter. The early traction of these accounts is validating our premium positioning. Physicians who have spent meaningful time with the system are confirming that this is a highly differentiated product on heart attack detection. Enrollment for the Align ACS pilot study is underway and we expect to have updates in the coming months on Head Start ACS and the Align ACS enrollment completion on AI with the Mount Sinai collaboration finalized, we're focusing on developing algorithms, including MI Focused and Wellness algorithms, with which will enhance the value of the heartbeam system for our initial patient population. And finally on the 12 lead patch, we're in the midst of partnership discussions and we added to this chart the pilot ischemia study on the patch, which is underway next. Tim will run us through the financials. Tim Cruikshank (Chief Financial Officer) Tim, great. Thanks Rob. This past month we strengthened our financial position through an $11.5 million financing. We closed the underwritten public offering of common stock on April 16th. Total gross proceeds of 10 million before cost and the underwriter as well exercised the overallotment option of 1.5 million in common stock for further gross proceeds. The offering was led by our first commercial customer, ClearCardio, alongside our executive leadership board members, a number of existing investors, as well as several fundamental institutional investors. This level of participation in the financing, including the fundamental institutional participation, is a strong signal of conviction in the business model and our trajectory. We ended March 31, 2026 with a cash balance of just over 2 million. So when you include the net proceeds from the recent offering and over allotment, we'd have a pro forma cash balance of approximately 12.4 million. This provides the cash Runway to advance Heartbeam into our next phase of growth and the common stock only financing continues to provide the company with a clean cap table and lots of optionality. Moving forward, our focus remains on execution towards our operational milestones while managing cash and dilution responsibly. We believe the progress we're making commercially combined with continued advanced development of our strategic initiatives that Rob walked us through, they position us well to execute in a meaningful way throughout 2026 and into 2027. Taking a look at the Q1 2026 financials, we had a net loss of 4.7 million with net cash used in operating activities of 3.6 million. This is a 19% decrease in operating cash outflow compared to the same quarter in the prior year. The Q1 spend and EPS came in ahead of expectations in Q1 of every year. There are several one time annual payments within it and we also made a few timely investments into our commercial Launch and the 12 lead patch development. Even with these investments, we continue to show our ability to execute on our aggressive milestones while still delivering the 19% year over year expenditure reduction we saw in the quarter. We've got a really lean but dedicated team and we continue to judiciously time our investments providing us with the ability to maintain a low cost profile. To that end, we previously stated our cash outflow expectations for 2026 would be in the 17 to 19 million dollars range. That was based on a more aggressive hiring of the sales team than we believe is necessary in the early days. As Brian described earlier, we have the ability to continue to prove out our initial commercial launch with the focused lean team. So based on that we estimate our cash outflow will be below 16 million for all of 2026. So if you take the cash outflows of 3.6 million in Q1 of this year, that equates to approximately 12 million in cash outflows for the remaining 3/4 for 2026 and that is prior to factoring in cash receipts from customers from our commercialization efforts. So this provides US funding into 2027 and the Runway necessary to accomplish several critical milestones we have ahead. In summary, the financing we closed this past month extends our Runway as we continue to advance our commercial launch and our exciting development initiatives in the 12 lead patch as well as our MI detection and AI initiatives combined with our balanced financial discipline including the 19% year over year reduction in operating cash burn delivered in Q1, we believe we have the cash Runway to advance Heartbeam well into our next phase of growth. With that, Rob, I'll turn it back over to you. Rob Eno (Chief Executive Officer) Thanks so much Tim. We're pursuing a massive $40 billion opportunity and we're executing on our plan to address major markets. The technology is significantly de risked with the achievement of the first ever FDA cleared cable free synthesized 12 lead ECG for arrhythmia assessment. The platform technology is backed by strong IP and clinical evidence. We strengthened our balance sheet with the April 2026 offering and we're following a capital efficient strategy with thoughtful and judicious timing of investments as as Tim laid out. And crucially, we're executing on multiple value creation opportunities in 2026 on the limited commercial launch. We have built flagship account presence in New York, Dallas, South Florida and Southern California. And our cost effective expansion strategy does not require a huge sales force on heart attack detection. We're rapidly advancing clinical validation to support indication expansion with the same Heartbeam system. The Align ACS pilot study is enrolling rapidly and is ahead of schedule. We believe that Heartbeam's on demand. 12 lead patch will be the best in class product in a $2 billion revenue market. With existing reimbursement. It will be the only 12 lead extended wear patch and its ability to detect ischemia as well as arrhythmia will be game changing. We've initiated the pilot study that's aimed at demonstrating the ischemia detection capabilities. We're advancing our efforts on a strategic partnership to speak adoption as well. And finally, the Mount Sinai agreement is key to our AI strategy and the development of next generation algorithms including MI detection and wellness algorithms. Longer term, we'll be partnering with Mount Sinai to create a new class of 12 lead screening and predictive algorithms that are with the patient at home. We thank you all for attending and now would like to open it up to Q and A operator. OPERATOR Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press Star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press Star two if you would like to remove your questions from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please. We poll for questions. The first question comes from the line of Kyle Bowser with Titan Partners Please go ahead. Kyle Bowser Hi, Rob, Tim and Brian. Thanks for taking my questions and congrats on all the recent progress here. It's impressive. Maybe I'll start with the commercial rollout. Following your two anchor partners. Can you talk about how many patients are collectively managed by these partners and also any updates on pricing? Are we still thinking the 500 to $1,000 range? Brian Humbarger (Chief Commercial Officer) Yeah. Hey, Kyle, this is Brian. Thanks for the question. So, yeah, as we've discussed, really this first half of the year is signing and getting these anchor accounts on board. So we're really focused on that. And as we move through the second half of, of Q2 and into the second half of the year, we will be, you know, focused much more on the adoption in those specific practices. There are number of patients in those specific practices aren't really shared publicly. But as we go back and look at why we focused on these specific geographies, looking at our premium value proposition and where the patients are, our focus is really on going after those 150,000 patients that are in this preventative concierge market and getting to 30,000 of those patients to our break even, our break even point. And when we look at these four markets, they represent, between the anchor accounts and other similar customers in the area, tens of thousands of patients in these specific geographies. So we feel very confident about that. Regarding the pricing, spot on, I think we talked about on the last call, 750 to 1,000 is what we look at from a pricing perspective on the, on the annual basis for the subscription fee and early indications that we haven't, we haven't received any pushback on that. So we're confident that we're coming in and being able to establish that value Rob Eno (Chief Executive Officer) right out of the gates and hey, Kyle, this is Rob. Great, great to hear from you. Just to add one quick thing, what Brian said, great answer, Brian. On the number of patients, as Brian said, because they're private accounts, they don't like us saying that. But I think you can expect in the near future, as we have more and more accounts, we'll be able to give a number that says collectively under these accounts, this number of patients, number of patients is being managed just like you're getting to. It's a little early because it exposes too much about the customers, but you can expect us to report that as part of what Brian said, some of the metrics that we're looking at. Kyle Bowser Okay, excellent. Makes sense. Appreciate that. And then maybe moving on to heart attack detection in the line ACS pilot study. Rob, I believe you mentioned previously it will be about 100 patients. Correct me if I'm wrong. And given the nice design of just enrolling ER chest pain patients, it sounds like it's ahead of schedule. Once you finalize the design for the pivotal study, can you talk a little bit about the timing and what that will look like for the enrollment of that pivotal. Rob Eno (Chief Executive Officer) Sure. So, yeah, the align ACS is on the order of 100 to 120 patients. It's enrolling well ahead of schedule. You know, we still believe we're comfortable in that enrollment by the end of. End of Q3. You know, what we're doing is, as I mentioned, is that study design we're learning a lot from. And that will inform the discussions with FDA for the pivotal study design. So we're in communication with FDA on everything from the regulatory pathway to the clinical study design. We're also talking with potential investigators in the US So nothing more to update in terms of further timing beyond align acs, but as soon as we know more, we'll make sure that we lay it out for you. Okay, appreciate that. Kyle Bowser And maybe I can just slip one more in regarding the Head Start ACS study. How will that differ from align ACS and number of patients, et cetera? Rob Eno (Chief Executive Officer) Yeah, we'll talk more about that in a little bit. But it's broadly the same design, meaning that it's looking at patients in emergency rooms with chest pain and comparing it to a 12 lead ECG. It's been sponsored by the government of Indonesia that's very interested in potential usage of our system. So it's going to be a bigger study on the order of 500 patients. And because of the design and the interest from Indonesia, it's largely paid for by the government. So it's a good opportunity for us to get more patients, both for our overall learning of the manual interpretation, but also, as I suggested, to be able to have a pool of patients to validate our upcoming AI algorithm. Well, so more details on that, you know, in the coming weeks, I believe. Okay, got it. Kyle Bowser Appreciate that. Thanks for taking my questions. OPERATOR Thank you. Next question comes from the line of Yi Chen with Etsy Rainwright. Please go ahead. Katie Hi, this is Katie on for Yi. I was hoping we could get a little bit more clarification on how we should model revenue from this subscription billing. Do you expect it to build consistently quarter over quarter, or is it going to be ebb and flow throughout the year? And then what is a realistic revenue expectation for full year 2026 with the current number of Deployed accounts. Tim Cruikshank (Chief Financial Officer) Great, thank you, Katie. Happy to take that. Go ahead, Tim. Yeah, thank you. So from a revenue perspective, it will be largely straight lined over the course of the year. It's all about performance obligations and, you know, and the commitment we have to, you know, these annual contracts with customers. So, you know, if you take $750 as an average price, you know, that's largely, you know, straight lined over the course of the year. There will be a portion that would, you may expect to see recognized earlier in the contract in recognition of some of the obligations we have of onboarding a customer, some of the additional costs required, you know, getting the device out the door, onboarding. And so there will be, you know, a slight higher portion of revenue early in the contract and then from there, straight lining of it, what's interesting or what's helpful to the company. The from a cash flow perspective, we expect the majority of customers to pay for the first year up front. So when you look at it from a PNL or from a cash perspective, you take the majority of that right up front. From a P and L perspective, it's straight lined, if that helps. Katie Great, thank you. Can I ask one follow up, looking at your discussion on deep adoption within those flagship accounts, can you give us an idea of what that full adoption looks like in a single practice? Like how many devices per practice and what does a fully penetrated flagship account generate annually? Rob Eno (Chief Executive Officer) Yeah, thanks for that. And again, we can't get really too far into the actual numbers at these accounts at this stage. But what I can tell you from an adoption standpoint is we're really looking at this from an onboarding process of the new patients on board, existing patients that are in the practice, and then another pool of patients that are actually coming to the practice because of the heartbeam technology. So what we will begin to start showing and sharing probably in the August timeframe is a little bit more detail on that question. And we'll have some more data to share. But again, we're tracking how far, how many patients within those given practices, the heartbeam technology benefits at a given time. And then I think as we continue forward, we're going to have additional strategies, but more to come on that I think we'll have much more detail for you in August. Tim Cruikshank (Chief Financial Officer) And then Katie, just to round out your question on revenue projections and then give you some insights for modeling in terms of, you know, what average accounts look like, you know, adding to what Brian said, we've said historically these early accounts have anywhere from 400 to 4,000 patients. If you take the kind of middle number of 2,000, anywhere from, you know, 500 to 1,000 of those patients, we would be expecting to get onto our technology, if not more. That's not going to be the case for massive rollout, you know, when we're scaling. But for these early accounts, you know, we're, we can get to 50% of those accounts from a modeling perspective. So say 1,000 patients at $1,000 or $750,000. That's 750,000 to a million dollars kind of per account. If you think about it that way. Not speaking specifically to these first two accounts, but just in terms of, in general. And the way we look at it is we've talked about 30,000 patients being our break even point. And it's a two year pathway to break even. If you take the very slow kind of methodical rollout of going after all of these smaller accounts individually. So to kind of back into the number of accounts or sites that would be required to get there over that time frame, you can back into those numbers. But what we believe is going to happen is if you break that 30,000 patient number down into about a third of them. Coming from this early segment, we believe we'll have the data points we need with these reference sites with the flagship accounts that are going to lead to channel partners and or distributors that are, sorry, chains, some of these large chains that would make up the next 20,000 wave of patients. So that's the way we plan to accelerate that timeline ahead of the kind of longer ground inbound, you know, two year, two and a half year timeframe. We get the initial adoption from about 10,000 patients in these smaller accounts, get the proof points we need and then we'll be able to quickly go to these larger chains and accelerate from there. Katie Great. Thank you guys, I appreciate it. OPERATOR Thank you. A reminder to all the participants that you may press Star and one to ask a question. We have no questions. Please go ahead. Rob Eno (Chief Executive Officer) We have a couple of webcast questions that we are going to take and the webcast question is, do you contemplate making your product known to investors and patients alike by producing television commercials to air on business channels like Fox Business, CNBC, etc. Yeah, I'll take that one. One of the things I really like about our strategy is that we don't need to do a DTC campaign direct to consumer campaign, which can be very, very expensive. We're targeting specifically accounts that have high net worth individuals. Our market research showed that high net worth individuals have a high Likelihood to pay. And interestingly, those who are in concierge practices willing to pay even more. So this is, we believe, the best way to access this market by, as Brian described, by going after a relatively small amount of practices, these practices work with us to, in a sense, sell it to their patients. So that's part of the reason why this strategy and our target of getting to 30,000 patients for breakeven can be done efficiently, because we sign a concentrated set of practices and then the practices work with us to drive deeper adoption. I will say though, that in early discussions with these practices, some of these practices are ones that have very well known personalities as patients and the physicians have expressed a willingness to work with us. If there's patients that are prominent that get on our technology, they may be interested in speaking on behalf of it. So that could come out organically with what we're doing. But we don't have plans to be spending for advertising, et cetera. We think this, In a sense, B2B model that we have now is the quickest and most efficient way to grow. Our next question asked, can you please walk us through management's thought process to not raise funds on the spike after approval and to wait until the price was under a dollar to raise capital? Tim Cruikshank (Chief Financial Officer) Sure, I can take that. Look, thank you for the question. I know it's on a lot of people's minds and so happy to take it. There's a number of factors that go into financing decisions. I think, you know, they stem from listening to current shareholders working within any commitments or historic covenants that might be present. But importantly as well, bringing the right new shareholders onto the register that are going to properly support the company and support the share price moving forward. I mean, this is especially true in the medical device space where additional funding is often required at the end of the day. The takeaways I have, we closed a clean deal with common stock only. We believe we brought very strong partners on in terms of long term investors onto the register. And now it's our job to continue to execute, bring visibility to the story and get the valuation to a level we all know this technology and the company deserves. And I think we've got a lot of optionality in terms of how clean we've kept the cap table, the types of, you know, institutional investors and retail investors we have on the register and with all the milestones we have ahead, you know, we're extremely confident in where we're headed and believe we can get this valuation to, you know, to the place that we all want it to be. OPERATOR Next question asks, do we expect Q2 revenue? Tim Cruikshank (Chief Financial Officer) Yeah, I'm happy to take that, Rob, if you want me to. Yeah. So we're right on track? Sure, yeah, Q1, we're right on track with all the plans we've laid out. Brian's done a great job providing updates and we're really excited about where we're headed. We will see some revenue in Q2, but as we've said from the beginning or for the last couple of quarters, the first half of the year, not a revenue story. We're not focused on, you know, driving revenue. We're focused on driving the right partners to this technology, proving deep adoption so that we have a repeatable scalable model for, you know, for the long term. And so there will be revenue and as well as cash receipts from customers to a small degree in Q2. And as we head into the second half of this year, that's when things start to get more exciting and we really put the funnel in place, give the visibility to them, to the street in terms of where we're headed for scaling revenue in 2027. So you can expect a little. But consistent with what we've said historically, it's all about getting the right people, the right accounts, you know, into the, into the technology and driving deep into those accounts so that we can show you the trajectory ahead. Rob Eno (Chief Executive Officer) And our last webcast question asks, could you elaborate on the medical professional's feedback on the product, how it's differentiating itself and justifying its use as opposed to traditional 12 lead systems? Specifically, do medical professionals think the more frequent measurements from heart mean are beneficial as opposed to taking measurements twice a month with a 12 lead? Brian Humbarger (Chief Commercial Officer) Great. Brian, do you want to handle that one and I'll follow? Yeah, yeah, I'll start out with that one. So it's a great question. The feedback has been actually exceeded my expectations coming into this. I've had a lot of experience with single and other multi lead technologies in the past. And what's clear from the clinicians is that with other technologies out there, it gives you a little bit of information and maybe opens the door on what's going on with the patient. But typically the next step for those patients where there's any concern whatsoever is bringing the patient into the office to get a 12 lead ECG or sometimes into the emergency department. So I think what's really been interesting to see with our clinicians is the fact that they can finally arm their patients with the same medical grade product that they and the same type of technology that if the patient was in the emergency department, they would be getting the full picture of what's going on with that patient. And now it's something that their patients can have anytime, anywhere. So it's been really encouraging to see that. Some of the feedback that we've heard, and we were just recently at the HRS conference and some of these other national or international conferences is to the second part of that question, I think, because there's never really been an opportunity to take 12 lead ECG outside of a hospital or clinic environment. There is a lot of interest to say, if we were to have our patients do this once a month or once a week and start looking at the data longitudinally, what are some of the things that we can learn? And again, as part of our early adopter experience, these are exactly the types of customers that we're focused on. They're bringing these types of questions. They're very eager to see what the data can provide and eyes wide open from the standpoint that no one's been able to do this before out of hospital setting on a consistent basis. Rob, anything to add? Rob Eno (Chief Executive Officer) Great answer, Brian. The only very little to add. I'll just say that the other thing which is interesting is some of the things we have in the pipeline that we've talked about before, such as wellness algorithms like Cardiac Age, that we can do off of the ECG. A 12 lead ECG is, we think, really differentiated and the physicians are quite excited about. OPERATOR That concludes our question and answer session. Thank you, ladies and gentlemen. We have reached the end of question and answer session. I would now like to turn the floor over to Mr. Eno for closing comments. Rob Eno (Chief Executive Officer) Thank you, operator. I'd like to thank each of you for joining our earnings conference call today. We look forward to continue to update you on our ongoing progress and growth. If we were unable to answer any of your questions today, please reach out to our IR firm, MZ Group, who would be more than happy to assist. Thank you very much. Disclaimer: This transcript is provided for informational purposes only. While we strive for accuracy, there may be errors or omissions in this automated transcription. For official company statements and financial information, please refer to the company's SEC filings and official press releases. Corporate participants' and analysts' statements reflect their views as of the date of this call and are subject to change without notice. UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. This article HeartBeam Q1 2026 Earnings Call: Complete Transcript originally appeared on Benzinga.com ﾩ 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.